Use of ustekinumab for severe refractory atopic dermatitis in a young teenager

Clinical and Experimental Dermatology

Volumn 41, Issue 6, 2016, Pages 625-627

  Wlodek, C ^a   Hewitt, H ^a   Kennedy, C T ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; STEROID; USTEKINUMAB;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; BODY WEIGHT; CASE REPORT; DERMATOLOGY LIFE QUALITY INDEX; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ERYTHRODERMIC PSORIASIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PSORIASIS; SCORING ATOPIC DERMATITIS SCORE; SCORING SYSTEM; SIDE EFFECT; STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84978194776     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12847     Document Type: Article

References (10)

1. Bieber T. Atopic dermatitis. N Engl J Med 2008; 35814: 1483–94.
2. Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 2014; 10503: 312–13.
3. Puya R, Alvarez-Lopez M, Velez A et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 2012; 511: 115–16.
4. Agusti-Mejias A, Messeguer F, García R, Febrer I. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 2013; 25: 368–70.
5. Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis – a report of two patients. J Eur Acad Dermatol Venereol 2016; 30: 522–23.
6. Brezinski EA, Armstrong AW. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis. Curr Med Chem 2015; 22: 1930–42.
7. Toda M, Leung DY, Molet S et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 1114: 875–81.
8. Koga C, Kabashima K, Shiraishi N et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 12811: 2625–30.
9. Moy AP, Murali M, Kroshinsky D et al. Immunologic overlap of helper t-Cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol 2015; 1517: 753–60.
10. Chandler D, Bewley A. Biologics in dermatology. Pharmaceuticals (Basel) 2013; 64: 557–78.